Diplomat Pharmacy Inc (NYSE: DPLO), an independent provider of specialty pharmacy services, is supplying Exelixis' limited-distribution treatment CABOMETYX (cabozantinib), now with an expanded indication, it was reported yesterday.
The product has been approved by the US Food and Drug Administration (FDA) as a first-line therapy indicated to treat patients with advanced renal cell carcinoma (RCC). It was initially approved as a second-line therapy for advanced RCC in 2016.
Joel Saban, Diplomat president, said, 'In supporting patients with advanced renal cell carcinoma, we are pleased to offer CABOMETYX as a new first-line treatment option. CABOMETYX tablets offer an important new alternative for patients seeking therapy options in the first-line setting and beyond."
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML